10
Loading video...

By Jeffrey Gerrish
Served as the Deputy U.S. Trade Representative for Asia, Europe, the Middle East, and Industrial Competitiveness from 2018 to 2020
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
President Donald Trump has reversed decades of failed U.S. trade policy and taken strong action to restore fairness and balance to our trade relationships with other countries.
By moving quickly and wielding the nation's economic leverage, President Trump has already secured major wins with some of the world's largest economies—and may now be poised to tackle one of the costliest imbalances of all: the foreign freeloading that drives up U.S. drug prices.
The White House has already secured critically important trade deals with the European Union, Japan, and South Korea. These agreements will bring hundreds of billions of dollars in foreign investment to key sectors like energy and semiconductors.
Read More
Will the Supreme Court Normalize Trump’s Economic Chaos? | Opinion5 min read

Mr. Trump, Stop Pushing India Away | Opinion5 min read

Trump Just Lost His Tariff Leverage. Secondary Sanctions Are His Last Chance | Opinion5 min read

The administration's wins on trade follow a significant diplomatic victory at NATO's June summit, where President Trump persuaded European leaders to commit to more than doubling their defense spending, ending a decades-long pattern of U.S. taxpayers shouldering the bulk of Europe's security costs.
These are pivotal victories. And they might lay the groundwork for tackling an even greater challenge: ending foreign freeloading on U.S. medical innovation. With America's trading partners now at the table, Trump has a chance to rewrite the rules of the pharmaceutical trade—ensuring U.S. innovation is rewarded, not exploited.

...
Europe, Japan, and South Korea have long used aggressive tactics to obtain cutting-edge medicines at below-market prices—forcing American patients to shoulder the costs of new drug research. The United States currently accounts for three-quarters of global pharmaceutical profits, despite representing just over a quarter of the world's GDP.
President Trump has floated a "Most Favored Nation" pricing policy, which would tie U.S. drug prices to the lowest prices paid abroad. While well intentioned, this approach would import harmful foreign price controls into the U.S., draining the funds needed for research and development. That would slow the flow of new treatments and leave American patients worse off.
A better solution would be to use America's trade leverage to dismantle the foreign policies that enable this freeloading in the first place.
In Europe, governments are moving to limit regulatory data protection for new medicines and make it easier to undermine drug patents. They also drag out pricing and reimbursement decisions well beyond the 180-day legal deadline, effectively shrinking the period of patent protection. These tactics reduce revenues for American firms and discourage the costly R&D investment necessary to develop new medicines.
Japan employs different policies with similar results. Many medicines face annual price cuts regardless of their effectiveness, and the government has also moved to claw back pricing premiums for innovative drugs—adding uncertainty for companies developing breakthrough treatments.
South Korea spends a smaller share of its drug budget on innovative medicines than any other high-income nation. It uses flawed cost-effectiveness metrics to justify underpaying for new treatments and imposes redundant, time-consuming reviews that significantly delay reimbursement and limit returns on research.
These practices suppress innovation and allow other countries to benefit from American breakthroughs at cut-rate prices. Ending such policies would be the most effective way to curb foreign freeloading and lower drug prices for Americans.
President Trump could push the EU, Japan, and South Korea to adopt fairer, freer pricing systems—making respect for intellectual property and appropriate valuation of U.S. treatments a condition of closer trade ties.
As with NATO, the president could also press these nations to shoulder more of the global burden for medical innovation. On a per-capita GDP basis, Japan spends about half as much as the U.S. on innovative medicines, with EU members and South Korea spending even less. Matching America's share would boost global R&D funding by tens of billions of dollars while spreading the costs more evenly among countries to ensure that other countries pay their fair share.
President Trump has already brought the world's largest economies to the negotiating table and reshaped trade terms to favor American industry. By applying the same strategy to pharmaceuticals, he can end foreign freeloading, lower U.S. drug prices, and preserve America's role as the global leader in both access and innovation.
Ambassador Jeffrey Gerrish served as the Deputy U.S. Trade Representative for Asia, Europe, the Middle East, and Industrial Competitiveness from 2018 to 2020.
The views expressed in this article are the writer's own.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines